Aridis Pharmaceuticals, Inc. (ARDS)

Market Cap	4.42M
Revenue (ttm)	19.65M
Net Income (ttm)	-9.62M
Shares Out	40.21M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	2.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	273,054
Open	0.100
Previous Close	0.090
Day's Range	0.090 - 0.122
52-Week Range	0.051 - 1.746
Beta	0.78
Analysts	Strong Buy
Price Target	10.00 (+8,990.91%)
Earnings Date	Aug 29, 2023

About ARDS

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 10, 2018
• Employees: 37
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARDS

Analyst Forecast

According to one analyst, the rating for ARDS stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(8,990.91% upside)

Analyst Consensus: Strong Buy